Point72 Asset Management
EWTX icon

Point72 Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Point72 Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593K Hold
14,600
– – ﹤0.01% 3104
2026
Q1 		$460K Buy
+14,600
New +$421K ﹤0.01% 3153
2025
Q2 		– Sell
-50,000
Closed -$1.1M – 2321
2025
Q1 		$1.1M Buy
+50,000
New +$1.31M ﹤0.01% 1413

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management's EWTX Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 117,262 shares worth $4.76M. The stake represents 0.01% of the portfolio and ranks #1798 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in EWTX as recently as Q4 2024.

Point72 Asset Management first reported a position in EWTX in Q2 2023 and has held it in 4 quarters since. The position peaked at $5.48M in Q4 2023. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Point72 Asset Management held 117,262 shares of Edgewise Therapeutics worth $4.76M as of Q2 2026.
  • Edgewise Therapeutics was a new Point72 Asset Management position in Q2 2026.
  • Edgewise Therapeutics made up 0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1798 holding.
  • Point72 Asset Management first reported a position in Edgewise Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • Point72 Asset Management's Edgewise Therapeutics position peaked at $5.48M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.